Schmidt P J Investment Management Inc. Has $4.25 Million Stock Position in Thermo Fisher Scientific Inc. $TMO

Key Points

• Schmidt P J Investment Management Inc. reduced its stake in Thermo Fisher Scientific by 8.8%, selling 827 shares and now owning a total of 8,542 shares worth approximately $4.25 million.
• Multiple institutional investors increased their positions in Thermo Fisher, with Vanguard Group Inc. acquiring an additional 230,382 shares, bringing its total to over 33.4 million shares valued at $16.66 billion.
• Thermo Fisher recently declared a dividend of $0.43 per share, scheduled for payment on October 15th, which equates to an annualized yield of about 0.4%.

Schmidt P J Investment Management Inc. decreased its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 8.8% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 8,542 shares of the medical research company's stock after selling 827 shares during the period. Schmidt P J Investment Management Inc.'s holdings in Thermo Fisher Scientific were worth $4,250,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently modified their holdings of the company. Vanguard Group Inc. raised its stake in shares of Thermo Fisher Scientific by 0.7% in the 1st quarter. Vanguard Group Inc. now owns 33,479,957 shares of the medical research company's stock worth $16,659,627,000 after buying an additional 230,382 shares in the last quarter. Amundi grew its holdings in shares of Thermo Fisher Scientific by 5.9% during the first quarter. Amundi now owns 3,029,044 shares of the medical research company's stock valued at $1,426,316,000 after buying an additional 168,197 shares in the last quarter. Charles Schwab Investment Management Inc. grew its holdings in shares of Thermo Fisher Scientific by 4.1% during the first quarter. Charles Schwab Investment Management Inc. now owns 2,925,591 shares of the medical research company's stock valued at $1,455,774,000 after buying an additional 115,463 shares in the last quarter. Pictet Asset Management Holding SA grew its holdings in shares of Thermo Fisher Scientific by 7.2% during the first quarter. Pictet Asset Management Holding SA now owns 2,879,274 shares of the medical research company's stock valued at $1,432,816,000 after buying an additional 193,378 shares in the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in shares of Thermo Fisher Scientific by 13.6% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,750,923 shares of the medical research company's stock valued at $1,368,859,000 after buying an additional 329,974 shares in the last quarter. Institutional investors own 89.23% of the company's stock.

Thermo Fisher Scientific Stock Down 2.4%

Shares of TMO traded down $11.93 during trading hours on Friday, hitting $479.48. 1,543,232 shares of the company were exchanged, compared to its average volume of 1,555,589. The company has a market cap of $181.06 billion, a PE ratio of 27.73, a PEG ratio of 2.62 and a beta of 0.75. The firm's 50 day moving average is $466.86 and its 200-day moving average is $451.65. Thermo Fisher Scientific Inc. has a 52 week low of $385.46 and a 52 week high of $623.77. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.50 and a current ratio of 1.93.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its quarterly earnings results on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.22 by $0.14. The company had revenue of $10.86 billion during the quarter, compared to the consensus estimate of $10.68 billion. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%.The firm's revenue was up 2.9% on a year-over-year basis. During the same quarter in the prior year, the company posted $5.37 EPS. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. On average, equities research analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 15th. Investors of record on Monday, September 15th will be given a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 0.4%. The ex-dividend date of this dividend is Monday, September 15th. Thermo Fisher Scientific's payout ratio is currently 9.95%.

Analysts Set New Price Targets

A number of research analysts have commented on the company. Raymond James Financial restated an "outperform" rating and issued a $535.00 target price (up previously from $525.00) on shares of Thermo Fisher Scientific in a research note on Thursday, July 24th. UBS Group boosted their target price on Thermo Fisher Scientific from $460.00 to $500.00 and gave the company a "neutral" rating in a research note on Thursday, July 24th. Hsbc Global Res downgraded Thermo Fisher Scientific from a "strong-buy" rating to a "hold" rating in a research note on Thursday, July 24th. Wall Street Zen downgraded Thermo Fisher Scientific from a "buy" rating to a "hold" rating in a research note on Sunday, September 7th. Finally, Barclays upgraded Thermo Fisher Scientific from an "equal weight" rating to an "overweight" rating and boosted their target price for the company from $490.00 to $550.00 in a research note on Thursday. Seventeen equities research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $592.24.

Insider Buying and Selling

In related news, EVP Gianluca Pettiti sold 400 shares of the business's stock in a transaction dated Friday, July 25th. The stock was sold at an average price of $479.98, for a total transaction of $191,992.00. Following the completion of the transaction, the executive vice president owned 22,367 shares of the company's stock, valued at approximately $10,735,712.66. The trade was a 1.76% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Marc N. Casper sold 10,000 shares of the business's stock in a transaction dated Friday, August 22nd. The stock was sold at an average price of $500.96, for a total value of $5,009,600.00. Following the transaction, the chief executive officer directly owned 115,174 shares of the company's stock, valued at $57,697,567.04. This represents a 7.99% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 30,066 shares of company stock valued at $14,182,963. Insiders own 0.33% of the company's stock.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.